Alam Kamran 4/A
4/A · Taysha Gene Therapies, Inc. · Filed Apr 10, 2025
Insider Transaction Report
Form 4/AAmended
Alam Kamran
CHIEF FINANCIAL OFFICER
Transactions
- Award
Employee Stock Option (right to buy)
2023-05-31+12,462→ 12,462 totalExercise: $1.18Exp: 2033-02-02→ Common Stock (12,462 underlying)
Footnotes (1)
- [F1]The option was awarded on February 2, 2023 by the Compensation Committee (the "Compensation Committee") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The shares underlying the option covered by this report vested upon certification. This option was inadvertently omitted for the original Form 4.